Nivolumab + ipilimumab ups melanoma response
- PMID: 25898833
- DOI: 10.1158/2159-8290.CD-NB2015-058
Nivolumab + ipilimumab ups melanoma response
Abstract
For patients with advanced melanoma, the combination of ipilimumab and nivolumab yields better responses than ipilimumab alone. However, the two-drug combination is much more likely to cause side effects than the monotherapy.
©2015 American Association for Cancer Research.
Comment on
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20. N Engl J Med. 2015. PMID: 25891304 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
